Fonseca Lidia

SEC source: 0001454944-26-000002 · wk-form4_1777493591.xml · nonDerivative · entry 2

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,644

F3 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.

SEC source: 0001454944-26-000002 · wk-form4_1777493591.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,851

F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.

F2 · balance_after: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person.

SEC source: 0001225208-26-003311 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,284

Underlying: Common Stock · 82,284 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-002817 · doc4.xml · derivative · entry 4

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,888 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-26-002817 · doc4.xml · nonDerivative · entry 3

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,455

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002817 · doc4.xml · nonDerivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,521

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002817 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,579

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001613103-25-000064 · wk-form4_1746044064.xml · nonDerivative · entry 2

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,675

F3 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.

SEC source: 0001613103-25-000064 · wk-form4_1746044064.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,891

F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.

F2 · balance_after: Includes 126 shares acquired through dividend reinvestment since the last report filed by the reporting person.

SEC source: 0001225208-25-003067 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,992

Underlying: Common Stock · 156,992 shares

Expires 2030-03-04

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-002704 · doc4.xml · derivative · entry 4

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 72,629 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002704 · doc4.xml · nonDerivative · entry 3

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,829

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002704 · doc4.xml · nonDerivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,851

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002704 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-24-008709 · doc4.xml · derivative · entry 4

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,038

Underlying: Common Stock · 38,038 shares

Expires 2029-02-24

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

F2 · derivative.expiration_date: Reflects a modification to the settlement date of the Modified TSRUs pursuant to the Modification Offer. The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008709 · doc4.xml · derivative · entry 3

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,038 shares

Expires 2027-02-24

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008709 · doc4.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,624

Underlying: Common Stock · 43,624 shares

Expires 2030-02-23

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

F2 · derivative.expiration_date: Reflects a modification to the settlement date of the Modified TSRUs pursuant to the Modification Offer. The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008709 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 43,624 shares

Expires 2028-02-23

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001613103-24-000048 · wk-form4_1714756117.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,682

F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.

SEC source: 0001613103-24-000029 · wk-form4_1714597965.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,844

F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.

F2 · balance_after: Includes 55 shares acquired through dividend reinvestment since the last report filed by the reporting person.

SEC source: 0001225208-24-003207 · doc4.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,124

Underlying: Common Stock · 60,124 shares

Expires 2031-02-27

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-24-003207 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,045

Underlying: Common Stock · 68,045 shares

Expires 2029-02-27

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001214659-23-006352 · marketforms-61366.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,039.39 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · shares: Includes 87.39 additional restricted stock units received by the reporting person as dividend equivalent restricted stock units in respect of the restricted stock unit grant.

F3 · derivative.exercise_date: The restricted stock units vested in four equal quarterly installments beginning on August 1, 2022. The last quarterly installment vested on May 1, 2023.

F3 · derivative.expiration_date: The restricted stock units vested in four equal quarterly installments beginning on August 1, 2022. The last quarterly installment vested on May 1, 2023.

SEC source: 0001214659-23-006352 · marketforms-61366.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,221.39

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

SEC source: 0001613103-23-000026 · wf-form4_168314602841816.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,624

F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.

SEC source: 0001225208-23-002812 · doc4.xml · derivative · entry 3

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,966

Underlying: Common Stock · 37,966 shares

Expires 2030-02-23

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-23-002812 · doc4.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,624

Underlying: Common Stock · 43,624 shares

Expires 2028-02-23

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001214659-22-008475 · marketforms-56576.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,952

Underlying: Common Stock · 5,952 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2022, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2023. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable, but no later than 30 days from the payment date or separation of service, as applicable, upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2023.

F2 · derivative.expiration_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2022, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2023. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable, but no later than 30 days from the payment date or separation of service, as applicable, upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2023.

SEC source: 0001225208-22-003463 · doc4.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,455

Underlying: Common Stock · 33,455 shares

Expires 2029-02-24

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-22-003463 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,038

Underlying: Common Stock · 38,038 shares

Expires 2027-02-24

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-22-001256 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,717

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001214659-21-005825 · marketforms-52905.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,593

Underlying: Common Stock · 6,593 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2021, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2022. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2022.

F2 · derivative.expiration_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2021, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2022. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2022.

SEC source: 0001214659-21-004902 · marketforms-52677.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,410 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · shares: Includes 206 additional restricted stock units received by the reporting person as dividend equivalent restricted stock units in respect of the restricted stock unit grant.

F3 · derivative.exercise_date: The restricted stock units vested in four equal quarterly installments beginning on August 1, 2020. The last quarterly installment vested on May 1, 2021.

F3 · derivative.expiration_date: The restricted stock units vested in four equal quarterly installments beginning on August 1, 2020. The last quarterly installment vested on May 1, 2021.

SEC source: 0001214659-21-004902 · marketforms-52677.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,182

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

SEC source: 0001225208-21-004043 · doc4.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,153

Underlying: Common Stock · 49,153 shares

Expires 2028-02-25

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-21-004043 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,888

Underlying: Common Stock · 56,888 shares

Expires 2026-02-25

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-21-001472 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,747

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F2 · price: Price is the closing price of Pfizer common stock on January 29, 2021.

SEC source: 0001214659-20-005212 · marketforms-48926.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,204

Underlying: Common Stock · 10,204 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2020, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2021. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2021.

F2 · derivative.expiration_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2020, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2021. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2021.

SEC source: 0001225208-20-003786 · doc4.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,117

Underlying: Common Stock · 59,117 shares

Expires 2027-02-27

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-20-003786 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,999

Underlying: Common Stock · 68,999 shares

Expires 2025-02-27

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-20-001563 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,310

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0000925421-19-000189 · edgar.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,668 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · shares: Includes 263 additional restricted stock units received by the reporting person as dividend equivalent restricted stock units in respect of the restricted stock unit grant.

F3 · derivative.exercise_date: The restricted stock units vested in four equal installments on each of August 1, 2018, November 1, 2018, February 1, 2019 and April 25, 2019.

F3 · derivative.expiration_date: The restricted stock units vested in four equal installments on each of August 1, 2018, November 1, 2018, February 1, 2019 and April 25, 2019.

SEC source: 0000925421-19-000189 · edgar.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

SEC source: 0000925421-19-000174 · edgar.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,926

Underlying: Common Stock · 7,926 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2019, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2020. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2020.

F2 · derivative.expiration_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2019, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2020. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2020.

SEC source: 0001225208-19-004209 · doc4.xml · derivative · entry 3

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,071

Underlying: Common Stock · 41,071 shares

Expires 2026-02-28

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-19-004209 · doc4.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,736

Underlying: Common Stock · 48,736 shares

Expires 2024-02-28

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-19-004209 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,510

F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0000925421-18-000202 · edgar.xml · derivative · entry 2

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,095 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · shares: The grant was previously reported as a grant of 5,000 restricted stock units, but was adjusted to reflect the completion of the previously-announced spin-off of the Issuer's digital automotive marketplace business on May 31, 2017. In addition, the amount includes 169 additional restricted stock units received by the reporting person as dividend equivalent restricted stock units in respect of the restricted stock unit grant.

F3 · derivative.exercise_date: The restricted stock units vested in four equal quarterly installments beginning on August 1, 2017.

F3 · derivative.expiration_date: The restricted stock units vested in four equal quarterly installments beginning on August 1, 2017.

SEC source: 0000925421-18-000202 · edgar.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,104

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

SEC source: 0000925421-18-000190 · edgar.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,405

Underlying: Common Stock · 11,405 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the underlying common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2018, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2019. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2019.

F2 · derivative.expiration_date: The restricted stock units vest in four equal quarterly installments beginning on August 1, 2018, except that the last quarterly installment shall vest on the earlier of the date of the next Annual Meeting of Stockholders of the Issuer and May 1, 2019. Unless delivery has been deferred by election of the reporting person, vested shares will be delivered to the reporting person as soon as administratively practicable upon the earliest to occur of the reporting person's separation from service with the Issuer, certain changes in control of the Issuer and May 1, 2019.